DNY59 In our last coverage of Viatris Inc. (NASDAQ?VTRS) we pointed out that the company was the epitome of a value trap. It looked cheap and appealed to the "low "P/E" crowd. But the melting ice cube prevented any returns for all but those that bought the extreme dips and sold the minor rips. The chart below shows the performance of VTRS and its predecessor, Mylan Labs. Mylan Labs was combined with the generic unit of Pfizer Inc. (PFE) and started trading as VTRS in November 2020. VAI Viatris Inc (VTRS) Pr ...